BUY Aurobindo Pharma — Aditya Agarwal, 09 Jun 2026

byAditya Agarwal, Coheron BrokersHorizon: NA (inferred Swing (≤2wk))9 Jun 2026via Business Today

Entry₹1,420Stated

Target₹1,550

Stop loss₹1,395-1.76% risk

Exit₹1,39515 Jun 2026, 2:15 pm

Stop-loss hit-1.76%

Follow Aditya Agarwal for new calls(32% target hit, 19 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Swing call on AUROPHARMA See 182 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Sept, 9:50 pm IST

4 supporting0 opposing

Supports the BUY call (4)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·10 Jun · 4d ago

Aurobindo Pharma Ltd has received final US FDA approval for its Tafacitinib tablets in 5 mg and 10 mg strengths. This approval is a significant regulatory milestone for the company's pharmaceutical pr

BSE · Company Update·4 Jun · 1w ago

Aurobindo Pharma Ltd is issuing a press release regarding the inauguration of Theranym, a large-scale biologics contract manufacturing facility in India.

BSE · Company Update·3 Jun · 2w ago

2 advisors have active short-term BUY calls on this stock

Advisor consensus · adjacent horizon·6 Apr · 2mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Aurobindo Pharma — Aditya Agarwal, Coheron Brokers

AI Assessment